CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis

Am J Hematol. 2023 Aug;98(8):E222-E225. doi: 10.1002/ajh.26988. Epub 2023 Jun 22.

Authors

Heinz-August Horst¹, Gerhard Zugmaier², Giovanni Martinelli³, Noemi Mergen², Kelly Velasco⁴, Faraz Zaman⁴, Hagop Kantarjian⁵

Affiliations

¹ Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany.
² Amgen Research (Munich) GmbH, Munich, Germany.
³ Scientific Directorate, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
⁴ Amgen Inc., Thousand Oaks, California, USA.
⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 37345570
DOI: 10.1002/ajh.26988

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Bispecific* / adverse effects
Antigens, CD19 / therapeutic use
Antineoplastic Agents* / adverse effects
Humans
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Recurrence

Substances

blinatumomab
Antibodies, Bispecific
Antineoplastic Agents
Antigens, CD19